Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-Ttherapy

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 6, 2010, Pages 381-387

  Gazdag, A ^a   Nagy, E V ^a   Burman, K D ^b   Paragh, G ^a   Jenei, Z ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Cardiovascular risk; Endothelial function; Hyperthyroidism; Hypothyroidism; Vascular injury markers

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTINE; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; LIPID;

ADULT; ARTICLE; BLOOD PRESSURE; BRACHIAL ARTERY; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HEMOSTASIS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IATROGENIC DISEASE; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID FUNCTION; THYROIDECTOMY; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; THYROID NEOPLASMS;

ADULT; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INFLAMMATION; LIPIDS; MIDDLE AGED; REGRESSION ANALYSIS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; TRIIODOTHYRONINE; VASODILATION;

EID: 77953652427     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1224156     Document Type: Article

References (50)

1. Arikan E, Karadag CH, Guldiken S. Asymmetric dimethylarginine levels in thyroid diseases. J Endocrinol Invest 2007 30 186-191
2. Attivissimo LA, Lichtman SM, Klein I. Acquired von Willebrand's syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism. Thyroid 1995 5 399-401
3. Biondi B, Fazio S, Carella C et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993 77 334-338
4. Biondi B, Palmieri EA, Fazio S et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000 85 4701-4705
5. Biondi B, Palmieri EA, Klain M et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005 152 1-9
6. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the L-arginine paradox and acts as a novel cardiovascular risk factor. J Nutr 2004 134 2842S-2847S discussion 2853S
7. Botella-Carretero JI, Gomez-Bueno M, Barrios V et al. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2004 11 345-356
8. Cappola AR, Fried LP, Arnold AM et al. Thyroid status, cardiovascular risk, and mortality in older adults. Jama 2006 295 1033-1041
9. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003 88 2438-2444
10. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002 87 1533-1538
11. Chadarevian R, Bruckert E, Ankri A et al. Turpin G. Relationship between thyroid hormones and plasma D-dimer levels. Thromb Haemost 1998 79 99-103
12. Chadarevian R, Bruckert E, Leenhardt L et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001 86 732-737
13. Christ-Crain M, Meier C, Guglielmetti M et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003 166 379-386
14. Cikim AS, Oflaz H, Ozbey N et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid 2004 14 605-609
15. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002 39 257-265
16. Danese MD, Ladenson PW, Meinert CL et al. Clinical review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J Clin Endocrinol Metab 2000 85 2993-3001
17. Diekman MJ, Harms MP, Endert E et al. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol 2001 144 339-346
18. Dietrich JB, Kuchler-Bopp S, Boutillier S et al. Expression of thyroid hormone receptors alpha and beta-1 messenger RNAs in human endothelial cells. The T3 hormone stimulates the synthesis of the messenger RNA of the intercellular adhesion molecule-1. Cell Mol Biol (Noisy-le-grand) 1997 43 1205-1212
19. Duggal J, Singh S, Barsano CP et al. Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management. J Cardiometab Syndr 2007 2 198-206
20. Fazio S, Palmieri EA, Lombardi G et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004 59 31-50
21. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: Evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002 87 1996-2000
22. Hak AE, Pols HA, Visser TJ et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000 132 270-278
23. Hermenegildo C, Medina P, Peiro M et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab 2002 87 5636-5640
24. Hiroi Y KH, Ying H, Furuya F et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006 103 (38) 14104-14109
25. Horne MK 3rd, Singh KK, Rosenfeld KG et al. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab 2004 89 4469-4473
26. Iervasi G, Molinaro S, Landi P et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007 167 1526-1532
27. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001 344 501-509
28. Lekakis J, Papamichael C, Alevizaki M et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997 7 411-414
29. Lien EA, Nedrebo BG, Varhaug JE et al. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metab 2000 85 1049-1053
30. Marongiu F, Biondi G, Conti M et al. Is a hypercoagulable state present in hypothyroidism? Thromb Haemost 1992 67 729
31. Marongiu F, Conti M, Mameli G et al. Fibrinog n and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 1988 11 723-725
32. McAllister RM, Grossenburg VD, Delp MD et al. Effects of hyperthyroidism on vascular contractile and relaxation responses. Am J Physiol 1998 274 E946-E953
33. Mercuro G, Panzuto MG, Bina A et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: Effect of individual dose tailoring. J Clin Endocrinol Metab 2000 85 159-164
34. Monzani F, Caraccio N, Kozakowa M et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: A double-blind, placebo- controlled study. J Clin Endocrinol Metab 2004 89 2099-2106
35. Muller B, Tsakiris DA, Roth CB et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001 31 131-137
36. Nagasaki T, Inaba M, Henmi Y et al. Change in von Willebrand factor and carotid intima-media thickness in hypothyroid patients with normal thyroid function after levothyroxine replacement therapy. Eur J Endocrinol 2004 150 125-131
37. Napoli R, Guardasole V, Angelini V et al. Acute effects of triiodothyronine on endothelial function in human subjects. J Clin Endocrinol Metab 2007 92 250-254
38. Obuobie K, Smith J, Evans LM et al. Increased central arterial stiffness in hypothyroidism. J Clin Endocrinol Metab 2002 87 4662-4666
39. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996 6 505-512
40. Osman F, Gammage MD, Franklyn JA. Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid 2002 12 483-487
41. Ozcan O, Cakir E, Yaman H et al. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2005 63 203-206
42. Papaioannou GI, Lagasse M, Mather JF et al. Treating hypothyroidism improves endothelial function. Metabolism 2004 53 278-279
43. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003 107 363-369
44. Rogers JS 2nd, Shane SR. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983 102 444-449
45. Sevim G, Hasan S, Nuri K. Effect of levothyroxine treatment on biochemical and haemostatic parameters in patients with hypothyroidism. Eur J Endocrin 2005 152 355-361
46. Simon A, Gariepy J, Chironi G et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002 20 159-169
47. Singh S, Duggal J, Molnar J et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: A meta-analysis. Int J Cardiol 2008 125 41-48
48. Taddei S, Caraccio N, Virdis A et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003 88 3731-3737
49. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003 108 2054-2059
50. Walsh JP, Bremner AP, Bulsara MK et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005 165 2467-2472.